Chemotherapy of experimental toxoplasmosis with special reference to robenidine
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
2974008
Knihovny.cz E-resources
- MeSH
- Guanidines therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Brain parasitology MeSH
- Mice MeSH
- Specific Pathogen-Free Organisms MeSH
- Pyrimethamine administration & dosage therapeutic use MeSH
- Robenidine administration & dosage therapeutic use MeSH
- Drug Administration Schedule MeSH
- Sulfadoxine administration & dosage therapeutic use MeSH
- Toxoplasmosis, Animal drug therapy MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Guanidines MeSH
- Pyrimethamine MeSH
- Robenidine MeSH
- Sulfadoxine MeSH
Robenidine as an anticoccidial agent alone (in doses of 50 and 100 mg/kg) or in association with two other antiprotozoal compounds--pyrimethamine and sulfadoxine (in doses of 2.5 and 250 mg/kg, respectively) were tested in the treatment of chronically infected mice with an avirulent cyst-forming HF strain of Toxoplasma gondii. The efficacy of the used drugs was evaluated by the cysts number in the brains of treated mice versus control group, antibody level and viability of survived cysts by the consecutive infection of mice. According to these criteria none of the tested drugs alone or combined exhibited to be able to produce an effective cure of cyst-stage of toxoplasmosis in experimental mice.